Andere Sprachen Poseida Therapeutics, Inc.

Aktien

A2PEYK

US73730P1084

PSTX

Markt geschlossen - Nasdaq Andere Börsenplätze 22:00:00 01.05.2024			% 5 Tage	% 1. Jan.
2,77 ^USD	+14,46 %		+33,82 %	-17,56 %

12:10	Poseida Therapeutics erhält bis zu 600 Millionen Dollar für Forschung und Entwicklung von Krebs-Gentherapie mit Xyphos	MT
01.05.	Poseida Therapeutics, Inc. und Xyphos Biosciences, Inc. schließen Forschungskooperation und Lizenzvertrag zur Entwicklung neuartiger allogener Zelltherapien in der Onkologie	CI

Andere Sprachen

Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!

100% kostenlose Registrierung

Poseida Therapeutics to Receive Up to $600 Million in Cancer Gene Therapy Research, Development Deal With Xyphos	12:10
Astellas and Poseida Therapeutics Enter Into Research Collaboration and License Agreement to Develop Novel Allogeneic Cell Therapies in Oncology	03:31
Malin Corp investee signs agreement with Astellas Pharma	01.05.
Poseida Therapeutics Shares Rise 18% After Licensing Deal With Xyphos Biosciences	01.05.
Astellas and Poseida Therapeutics Enter Into Research Collaboration and License Agreement to Develop Novel Allogeneic Cell Therapies in Oncology	01.05.
Poseida Therapeutics, Inc. and Xyphos Biosciences, Inc. Enter into Research Collaboration and License Agreement to Develop Novel Allogeneic Cell Therapies in Oncology	01.05.
Poseida Therapeutics Announces Strong Lineup of Presentations at the American Society of Gene and Cell Therapy 27th Annual Meeting	19.04.
Poseida Therapeutics Hosts Gene Therapy R&D Day Highlighting New Scientific Advancements and Pipeline Focus	17.04.
Poseida Therapeutics, Inc. Presents New Phase 1 Data at AACR 2024 Supporting Potential of P-BCMA-Allo1 Allogeneic CAR-T Therapy to Benefit Broad Range of Patients with Multiple Myeloma	08.04.
Poseida Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)	01.04.
Poseida Therapeutics Appoints Syed Rizvi as Chief Medical Officer	25.03.
Poseida Therapeutics, Inc Appoints Syed Rizvi as Chief Medical Officer Effective April 1, 2024	25.03.
Poseida Therapeutics to Present at H.C. Wainwright 2nd Annual Cell Therapy Virtual Conference	19.03.
Poseida Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	07.03.
Earnings Flash (PSTX) POSEIDA THERAPEUTICS Reports Q4 Revenue $25M	07.03.
Poseida Therapeutics : Provides Updates and Financial Results for the Fourth Quarter and Full Year 2023 - Form 8-K	07.03.
Poseida Therapeutics, Inc. Announces Executive Changes	07.03.
Poseida Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	07.03.
Poseida Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)	04.03.
Poseida Therapeutics, Inc.(NasdaqGS:PSTX) dropped from NASDAQ Biotechnology Index	15.12.

Keine Ergebnisse zu dieser Suche

Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Andere Sprachen Poseida Therapeutics, Inc.

Aktien

A2PEYK

US73730P1084

PSTX

Andere Sprachen

Filter